Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Expected to Rise, Truist Financial Analyst Says

Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target increased by Truist Financial from $30.00 to $33.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s price objective points to a potential upside of 47.19% from the company’s current price.

CNTA has been the subject of several other research reports. Wall Street Zen upgraded shares of Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, October 27th. Stephens assumed coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, October 28th. They set an “overweight” rating and a $35.00 target price for the company. Wells Fargo & Company lifted their price target on shares of Centessa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, October 8th. Finally, Chardan Capital reissued a “buy” rating and set a $30.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, January 2nd. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Centessa Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Centessa Pharmaceuticals Stock Up 1.7%

Shares of CNTA stock opened at $22.42 on Thursday. Centessa Pharmaceuticals has a 1 year low of $9.60 and a 1 year high of $30.58. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. The business’s fifty day moving average is $26.04 and its 200-day moving average is $21.34. The stock has a market cap of $3.01 billion, a PE ratio of -12.25 and a beta of 1.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). Equities analysts expect that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Mario Alberto Accardi sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction on Monday, December 8th. The stock was sold at an average price of $30.00, for a total transaction of $300,000.00. Following the transaction, the insider owned 178,801 shares in the company, valued at approximately $5,364,030. The trade was a 5.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CTO Tia L. Bush sold 40,000 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $26.00, for a total value of $1,040,000.00. Following the transaction, the chief technology officer directly owned 121,503 shares in the company, valued at $3,159,078. The trade was a 24.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 64,000 shares of company stock worth $1,674,460. Corporate insiders own 7.09% of the company’s stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Centessa Pharmaceuticals in the second quarter worth approximately $218,000. American Century Companies Inc. increased its stake in Centessa Pharmaceuticals by 3.5% in the 2nd quarter. American Century Companies Inc. now owns 1,130,708 shares of the company’s stock valued at $14,858,000 after buying an additional 37,954 shares during the period. Bollard Group LLC purchased a new stake in Centessa Pharmaceuticals in the 2nd quarter worth approximately $1,319,000. Ensign Peak Advisors Inc boosted its stake in shares of Centessa Pharmaceuticals by 27.8% during the 2nd quarter. Ensign Peak Advisors Inc now owns 559,744 shares of the company’s stock valued at $7,355,000 after buying an additional 121,611 shares during the period. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of Centessa Pharmaceuticals during the 2nd quarter valued at $725,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.